<DOC>
	<DOCNO>NCT00316589</DOCNO>
	<brief_summary>The purpose study gather information safety immunogenicity investigational smallpox vaccine HIV infect population . Subjects receive two vaccination</brief_summary>
	<brief_title>Safety Immunogenicity IMVAMUNE® ( MVA-BN® ) Smallpox Vaccine HIV Infected Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Smallpox</mesh_term>
	<criteria>Genders eligible Study : Both Age : 18 55 year Healthy volunteer accept Subjects test positive HIV1 infection . Subjects test negative HIV . Either stable antiretroviral therapy antiretroviral therapy . CD4 cell &gt; = 200 750/µl . Subjects must good general health except HIV infection . Women must pregnant use acceptable method contraception . Impairment immunologic function ( HIV infection ) . History coronary heart disease , myocardial infarction , angina , congestive heart failure , cardiomyopathy , stroke transient ischemic attack , uncontrolled high blood pressure . Uncontrolled serious infection . History active autoimmune disease . History clinical manifestation clinically significant severe hematological , renal , hepatic , pulmonary , central nervous , cardiovascular gastrointestinal disorder . History immediate family member ( father , mother , brother , sister ) onset ischemic heart disease age 50 year . High risk develop myocardial infarction coronary death . History intravenous drug abuse ( within last 12 month ) . Known allergy egg aminoglycoside ( gentamicin ) . History anaphylaxis severe allergic reaction . Subjects undergoing treatment tuberculosis infection disease . Chronic administration systemic immunosuppressant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HIV</keyword>
	<keyword>treatment experience</keyword>
	<keyword>treatment vaccinia naive</keyword>
</DOC>